

June 5, 2023

For Private Circulation Only

	PREv CLOSe	OpeN	HiGh	LoW	CLOSe	Net CHNg (POINTs)	Net CHNg (%)
BSe SENSEx	62547	62759	62943	62752	62787	↑ 240	0.38%
NSe NiFTy	18534	18612	18640	18583	18594	↑ 60	0.32%
NIFTy MiDCAp 100	33967	34113	34170	33984	34015	↑ 48	0.14%

D-STREET END In THE GREEN BUT OFF HIGHs...!!!

Indian shares ended higher on Monday, powered by sustained gains in auto stocks and tracking the mood in the broader Asian market, as mixed U.S. jobs data bolstered bets that the Federal Reserve may skip an interest rate hike later this month. Most sectoral indices ended in the green with Auto jumping more than 1%.

Bse Sector: Gainers: Auto, Capital Goods, Industrials, Utilities, Power, Consumer Discretionary, Consumer Durables, Commodities, Bankex, Metal, Financial Services, Realty, Energy, Oil & Gas, Telecommunication, Healthcare **Losers:** FMCG, IT, Teck

ASIAN INDICES						EUROPEAN INDICES*			
CHINa	0.07%	HONGKONGg	0.84%	JAPAn	2.20%	FRANCe	-0.16%	Uk	0.49%
SINGAPORe	0.72%	S KOREa	0.54%	TAIWAn	0.05%	GERMANY	0.00%		
CBOe ViX (02-06-23)					US DOLLAR INDEX*				
15.18					104.262				

TATa CHEMICALs : CMP Rs.996 (+3%)

Tata Chemicals soared on the back of strong volumes as the company announced the restructuring of its US operations. In addition, the Tata Group's Rs.13,000-crore capital expenditure plans to setup a giga lithium-ion manufacturing facility in Gujarat also aided sentiment. The company also announced revising the holding structure of its US operations from June 1 to reduce the number of intermediate entities. The restructuring move saw Tata Chemicals (Soda Ash) Partners undergoing a transformative conversion from a partnership into a limited liability company (LLC). As part of this transition, the entity will be rebranded as Tata Chemicals (Soda Ash) Partners LLC. Additionally, the restructuring plan also includes the merger of two intermediate holding entities, TC (Soda Ash) Partners Holdings and TCSAP LLC, into the newly formed Tata Chemicals (Soda Ash) Partners LLC.

TATa MOTORs (#) : CMP Rs.546 (+2%)

The Tata Group, through its subsidiary, Agratas Energy Storage Solution, has signed a MoU with the Government of Gujarat for its capital expenditure plans in the state. The move will significantly support the development of the electric-vehicle (EV) industry in India. According to an official announcement by the Gujarat government, the project is set to commence with an initial investment of Rs.13,000 cr (equivalent to USD 1.8 bn) during its first phase. This endeavour aims to establish a factory with a substantial capacity of 20 gigawatts (GW), furthering the government's push towards achieving 100% EV adoption and reduction in carbon emissions by 50% by 2030.

PVr INOX LTD : CMP Rs.1431 (+2%)

PVR INOX Ltd announced the launch of a new 7-screen multiplex in Bengaluru. With this, PVR INOX's foothold in South India has increased to 530 screens in 95 properties. The multisensory 4DX auditorium is housed in Global Mall located next to Nayandahalli Metro Station and has a seating capacity of 1189 with last row recliners, said the company in an exchange filing.

BIOCOn (#) : CMP Rs.241 (+1%)

Biotechnology company Biocon has informed that the USFDA concluded a surveillance and pre-approval inspection of Biocon Pharma Limited Oral Solid Dosage formulations manufacturing facility at Bengaluru on June 2 and issued 'no observations' on completion.

Dr REDDY's LABORATORIEs (#) : CMP Rs.4611 (0%)

Dr Reddy's Laboratories announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study. This Phase I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr. Reddy's tocilizumab biosimilar candidate in comparison to reference products, company said. The clinical trial also confirmed the similarity between DRL_TC and the EU and US reference products in terms of pharmacodynamic parameters and found no noteworthy differences in safety and immunogenicity across these three treatment groups. The company is developing the proposed tocilizumab biosimilar as both intravenous and subcutaneous formulations.

BEATING tHe STREET (Nifty): Gainers were MnM, AxisBk, TataMtr, LT, Grasim, TataStl, SBILife, IndsindBk, Maruti, UPL, Cipla, ICICIBk, SunPhrm
EXPECTATIOn BELIEd (Nifty): Losers were DivisLab, TechM, AsianPaints, Nestle, BPCL, HUL, HeroM, EchrMtrs, KtkMah, ITC, CIL, TCS, AdaniEntr

MARKET BREADTh

ADVANCES	DECLINES	UNCHANGED	TOTAL
2160 (56%)	1498 (39%)	182 (5%)	3840 (100%)

TURNOVER			CUM-DIV NSE 500				CUM- BASIS NSE 500		
	05-06-23	02-06-23	Company	EX DATE	05-06-23	Div	Company	EX DATE	ACTION
Bse	4238	3576	NELCO	06-06-23	634	2.00	NIITLTD	08-06-23	DEMERGER
Nse	57725	59212	PRIMESECU	06-06-23	117	0.50	IONEXCHANG	12-06-23	FV SPLIT 10-1
NSe FO	10604911	12810462	SESHAPAPER	07-06-23	284	6.00			
NSe FPT**	41121	52633	TATAPOWER	07-06-23	219	2.00			

VOLUME SHOCKERS (BSE) (Shares in LAKHS)

TATASTEEL	22.91	WELSPUNIND	11.27
TATAMOTORS	7.87	RVNL	5.78

*Values recorded at the time of preparation of product * ** NSE F&O Premium Turnover

Identification Suffixes: ## Fundamental Reports, # Universe, N.A (Data not available)

Please Note that our technical calls are totally independent of our fundamental calls.

Additional information with respect to any securities referred to herein will be available upon request.

nishitass@sushilfinance.com

Sushil Financial Services Private Limited

Member : BSE / NSE - SEBI Regn. No. INZ000165135 | Research Analyst - SEBI Registration No. INH000000867

Tel.: 022-6698 0636 Fax: 022-6698 0606 E-mail: info@sushilfinance.com

Disclaimer & Disclosures:

<https://www.sushilfinance.com/Disclaimer/research>

<http://goo.gl/1sOHe>

This report has been furnished to you for your general information only and should not be reproduced, re-circulated, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of Sushil Financial Services Private Limited. This Research Report is meant solely for use by the original recipient to whom it is sent and is not for circulation. Any unauthorized use, disclosure or public dissemination or copying of information (either whole or partial) contained herein is prohibited.

This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice/offer for the purpose of purchase or sale of any securities mentioned herein. Past performance is not a guide for future performance, future returns are not guaranteed. Opinions expressed herein are subject to change without notice. Investor should rely on information/data arising out of their own investigations. The Sushil Equity Universe consists of ## Sushil's Classic - the company's where fundamental reports are published and # Sushil's Bonanza - the other company's under study.

Investors are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investor may realize losses on any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by us to be reliable. A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com Research Analyst views on Subject Company may vary based on Fundamental and Technical Research. Sushil Financial Services Private Limited or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. None of the directors, employees, affiliates or representatives of company shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages/loss etc whatsoever from the information/opinions/views contained in this Report and investors are requested to use the information contained at their risk.

Sushil Financial Services Private Limited (SFSPL) and its connected companies, and their respective Directors, Officers and employees or their relative, may have a long or short position in the subject companies mentioned in the report and it may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Reports based on technical and derivative analysis centre on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. SFSPL has different business segments/Divisions with independent research and maintains arm's length distance catering to different set of customers having various objectives, risk profiles, investment horizon, etc. and therefore may at times have different contrary views on stocks sector and markets. Research Report may differ between SFSPL's RAs on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold - SFSPL, its employees and associates responsible for any losses, damages of any type whatsoever.

This Report is not intended to be a complete statement or summary of the securities, market or developments referred to in this document. SFSPL or its affiliates or employees are under no obligation to update the information. SFSPL or its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report.

SFSPL or its affiliates and/or its employees/its associates or his relative does not have financial interest in the subject companies. SFSPL or its affiliates and/ or its employees/its associates or his relative may or may not have beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report. SFSPL/its Associates/ Research Analyst have not received any compensation from the subject company in the past twelve months. Further the subject company is/was not a client during twelve months preceding the date of distribution of the research report and the types of services provided. SFSPL or its research analyst has not served as an officer, director or employee of the subject company. SFSPL or its affiliates and/or its research analysts have not been engaged in market making activity for the subject company. SFSPL or its associates or its Research Analyst have not received any compensation or other benefits from the subject companies or third party in connection with the research report. SFSPL/its Associates/ Research Analyst/ his Relatives not have any other material conflict of interest at the time of publication of the research report.

SFSPL/its Associates/ Research Analyst have not managed or co-managed public offering of securities, have not received compensation for investment banking or merchant banking or brokerage services, have not received any compensation for product or services other than investment banking or merchant banking or brokerage services from the subject companies in the last twelve months. There is no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

Additional information with respect to any securities referred to herein will be available upon request.

Sushil Financial Services Private Limited

Member : BSE / NSE - SEBI Regn. No. INZ000165135 | Research Analyst – SEBI Registration No. INH000000867

Tel.: 022-6698 0636 Fax: 022-6698 0606 E-mail: info@sushilfinance.com